Company intelligence / Profile preview
Mesenkia Therapeutics
Uppsala, Uppsala län, Swedenmesenkiatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Mesenkia Therapeutics is in the pre-clinical stage, developing an antibody-based therapy targeting HVEM for glioblastoma. The approach aims to inhibit tumor growth and activate the immune system, with hopes of extending patient survival. No clinical results are available yet as programs are not in human trials.
- Therapeutic areas
- Oncology
- Modalities
- AntibodyBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Uppsala University (Sweden)University of Tokyo (Japan)
Beyond the preview
Go deeper on Mesenkia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mesenkia Therapeutics.